February 27, 2015
MTPC President Masayuki Mitsuka Mitsubishi Tanabe Pharma Corporation (MTPC) is looking to pull in combined sales of at least 100 billion yen in Japan from the company’s two anti-human TNFα monoclonal antibodies, Remicade (infliximab) and Simponi (golimumab). “We want to...read more